{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stavraka C"],"funding":["CSP VA","Cancer Research UK","British Skin Foundation","Worldwide Cancer Research","Breast Cancer Now","Cancer Research UK King's Health Partners Centre at King's College London","Medical Research Council","CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre","The Cancer Research UK City of London Centre"],"pagination":["2225-2239"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12368751"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["80(8)"],"pubmed_abstract":["Background
IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary signs of efficacy in a Phase I trial. Treatment was well tolerated, with the most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated with urticarial skin reactions in MOv18 IgE-treated patients.Methods
Expression of target antigen, FRα, and MOv18 IgE reactivity with FRα or any component in human skin was studied by immunohistochemistry, immunofluorescence and immuno-mass spectrometry. We conducted transcriptomic analyses in paired lesional and non-les"],"journal":["Allergy"],"pubmed_title":["Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha."],"pmcid":["PMC12368751"],"funding_grant_id":["573","147;KCL-BCN-Q3","006/R/22","C30122/A11527;C30122/A15774","C604/A25135","C7893/A29290","MR/L023091/1;MR/V049445/1;MR/R015643/1","24-0087","C10355/A15587"],"pubmed_authors":["Tull TJ","Lacy KE","McGrath J","Chauhan J","Stavraka C","Gillett C","Kristeleit R","McSweeney SM","Di Meo A","Till SJ","Pinder S","Prassas I","Pope A","Stoker K","Willsmore Z","Bax HJ","Spicer J","Crescioli S","Karagiannis SN","Grattan CEH","Tsoka S","McCraw AJ","Diamandis EP","Josephs DH","Naban N","Adams R","Corrigan CJ","Semkova KV","Laddach R"],"additional_accession":[]},"is_claimable":false,"name":"Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha.","description":"Background
IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary signs of efficacy in a Phase I trial. Treatment was well tolerated, with the most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated with urticarial skin reactions in MOv18 IgE-treated patients.Methods
Expression of target antigen, FRα, and MOv18 IgE reactivity with FRα or any component in human skin was studied by immunohistochemistry, immunofluorescence and immuno-mass spectrometry. We conducted transcriptomic analyses in paired lesional and non-les","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-07-15T06:22:42.211Z","creation":"2026-07-01T03:07:22.999Z"},"accession":"S-EPMC12368751","cross_references":{"pubmed":["40045925"],"doi":["10.1111/all.16514"]}}